11
2
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T7714 |
Temocapil
|
Tyrosinase | Proteases/Proteasome |
Temocapil 是一种酪氨酸激酶抑制剂。 | |||
T6698 |
Temocapril hydrochloride
CS-622 HCl,Acecol,Temocapril HCl,CS-622,盐酸替莫普利 |
RAAS | Endocrinology/Hormones |
Temocapril hydrochloride (CS-622 HCl) 是血管紧张素转化酶 (ACE) 抑制剂。Temocapril HCl 能够用于充血性心力衰竭、急性心肌梗死、高血压、胰岛素抵抗和肾脏疾病的研究。 | |||
T50000 |
2-Iodohippuric Acid
|
Others | Others |
2-Iodohippuric Acid 可以用来测量肾脏的清除率用于肾功能研究,也用于某些疾病的诊断,如肝病和肾病。此外,它还用于某些药物的合成。 | |||
T1182 |
Levocarnitine propionate hydrochloride
Propionyl-L-carnitine hydrochloride,L-Propionylcarnitine chloride,丙酰左旋肉碱盐酸盐,ST-261,丙酰肉碱盐酸盐 |
Histamine Receptor | GPCR/G Protein; Immunology/Inflammation; Neuroscience |
Levocarnitine propionate hydrochloride (ST-261) 可用于肾功能恶化,充血性心脏衰竭,间歇性跛行等疾病的研究。 | |||
T8366 |
Mitochonic acid 5
MA-5 |
Mitochondrial Metabolism | Metabolism |
Mitochonic acid 5 (MA-5) 能够调节线粒体 ATP 合成,可与线粒体结合,并改善肾小管和心肌细胞损伤。 | |||
T16808 |
Runcaciguat
|
Others; Guanylate cyclase | GPCR/G Protein; Others |
Runcaciguat 是一种可溶性鸟苷酸环化酶刺激剂。 Runcaciguat 与特异性部分腺苷 A1 受体激动剂相结合,可用于心血管和肾脏疾病的研究。 | |||
T11412 |
IPN60090
GLS1-IN-1 |
Others; transporter | Metabolism; Others |
IPN60090是一种新型、强效、口服生物利用度高的 肾型谷氨酰胺酶(GLS1)特异性抑制剂,对GLS1的IC50值为31 nM。IPN60090 具有潜在的抗癌和免疫刺激/免疫调节活性,可选择性地靶向、结合并抑制人谷氨酰胺酶,可用于研究 GLS1 介导的疾病。 | |||
T39611 |
Enuvaptan
Enuvaptan,BAY-2327949 |
||
Enuvaptan is a vasopressin receptor antagonist and has the potential for research into renal and cardiovascular diseases. | |||
T71450 |
Ilacirnon sodium
|
||
Ilacirnon sodium is a potent CCR2 antagonist that may be useful in the treatment of renal diseases including Focal Segmental Glomerulosclerosis and Diabetic Nephropathy. | |||
T76762 | Tabalumab | ||
Tabalumab (LY2127399) 是一种人源化的抗BAFF(B 细胞激活因子) 单克隆抗体 (IgG4 型),对膜结合和可溶性BAFF 具有中和活性。Tabalumab 可用于自身免疫性疾病,如类风湿性关节炎、肾衰竭和系统性红斑狼疮的研究。 | |||
T70990 |
ADMA-d6
|
||
NG,NG-dimethyl-L-arginine-d6 (ADMA-d6) (hydrochloride) is intended for use as an internal standard for the quantification of NG,NG-dimethyl-L-arginine by GC- or LC-MS. ADMA is an endogenous inhibitor of nitric oxide synthase (NOS). It is formed from arginine by protein arginine methyltransferases (PRMTs) and degraded by dimethylarginine dimethylaminohydrolases (DDAHs) and alanine-glyoxylate aminotransferase 2 (AGXT2). ADMA levels are increased concomitant with an increase in blood pressure in Da... |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T8053 |
N-Acetyl-L-arginine
N-Α-乙酰-L-精氨酸,Ac-Arg-OH |
Endogenous Metabolite | Metabolism |
N-Acetyl-L-arginine (Ac-Arg-OH) 是一种胍基诺化合物,被发现存在于血液渗析性肾不足儿童患者血清中的。 | |||
TN3753 |
Dalbergioidin
|
Tyrosinase; ROS; Akt; PI3K; TGF-beta/Smad | Cytoskeletal Signaling; Immunology/Inflammation; PI3K/Akt/mTOR signaling; Proteases/Proteasome; Stem Cells |
Dalbergioidin exhibits tyrosinase inhibitory activity with an IC50 of 20 mM. It shows a melanin biosynthesis inhibition zone in the culture plate of Streptomyces bikiniensis that has commonly been used as an indicator organism. Dalbergioidin protects MC3T3-E1 osteoblastic cells against H2O2-induced cell damage through activation of the PI3K/AKT/SMAD1 pathway, suggests that it may be useful in bone metabolism diseases, particularly osteoporosis. Dalbergioidin also ameliorates doxorubicin-induced ... |